Trial Profile

A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Ethambutol (Primary) ; Isoniazid (Primary) ; Pretomanid (Primary) ; Pyrazinamide (Primary) ; Quabodepistat (Primary) ; Rifampicin (Primary) ; Sutezolid (Primary)
Indications Pulmonary tuberculosis
Focus Adverse reactions

25 Feb 2025 Status changed from active, no longer recruiting to discontinued, because the data generated in this study do not support the ability of investigational drugs as a new regimen to treat tuberculosis in 3 months or less.
01 Oct 2024 Planned End Date changed from 31 Oct 2024 to 31 Jan 2025.
01 Oct 2024 Planned primary completion date changed from 31 Oct 2024 to 31 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com